An observational study in Knee Injuries, sponsored by EMO Biomedicine Corporation. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-09-10.
Sponsored by EMO Biomedicine Corporation · Observational
According to many researches, mesenchymal stem cells (MSC) isolated from synovial membrane and infrapatellar fat pad have higher ex vivo proliferation capacity, multipotency and ability to undergo chondrogenesis.
Based on this concept, the investigators plan to get two removed tissues (synovial membrane and infrapatellar fat pad) from patients who have an operation of TKR (Total Knee Replacement). The investigators are going to isolate and expand MSC from these two tissues respectively, and then compare their characterization and potential for clinical application. In the other hand, the investigators plan to build techniques and procedures which comply with "Good Tissue Practices (GTP)".
249 studies on the registry are indexed under Knee Injuries; 48 are open to participants now.
This study's enrollment of 6 is below the median of 90 across 79 observational studies indexed under Knee Injuries.
Browse Knee Injuries studies →EMO Biomedicine Corporation is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
For patients who have an operation of total knee replacement.
Patient who have an total knee replacement surgery
Exclusion Criteria:
Patient who don't sign the agreement
Compare MSCs from synovial membrane and infrapatellar fat pad
Comparison items include doubling time, phenotype, chondrogenesis and biological activity.
Time frame: 2 months
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
EMO Biomedicine Corporation